Leukemia researchers have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.
René Marke, theme Cancer development and immune defense, was part of the project during his graduation research for the master's program Molecular Mechanisms of Disease (MMD).They have also identified two distinct stem-cell like populations from which relapse can arise in different patients in this aggressive cancer that they previously showed starts in blood stem cells in the bone marrow. These findings, recently published in Nature, provide significant insights into cell types fated to relapse and can help accelerate the quest for new, upfront therapies.
AML is a blood cancer that affects white blood cells known as myeloid cells. The cancer cells accumulate in the bone marrow, where they interfere with normal blood cell production.
Related news items
T cell immunity is directed by tetraspanin CD53
5 July 2022 T cells are immune cells that are key for the defense against pathogens and cancer. T cells depend on the membrane protein CD45 to initiate T cell receptor signaling, but how CD45 is controlled at the molecular level is poorly understood. read moreA single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta
21 June 2022 The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. read moreDutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs
14 June 2022 The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma. read moreEuropean grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant
26 April 2022The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.
read more